269 related articles for article (PubMed ID: 28969581)
1. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.
Kaboli PJ; Bazrafkan M; Ismail P; Ling KH
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581
[TBL] [Abstract][Full Text] [Related]
2. Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth.
Wang J; Peng Y; Liu Y; Yang J; Ding N; Tan W
BMC Cancer; 2015 Aug; 15():595. PubMed ID: 26296751
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.
Manetti F; Petricci E
Expert Opin Ther Pat; 2016; 26(4):529-35. PubMed ID: 26666870
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
[TBL] [Abstract][Full Text] [Related]
5. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
[TBL] [Abstract][Full Text] [Related]
6. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
7. The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injury.
Grzelak CA; Martelotto LG; Sigglekow ND; Patkunanathan B; Ajami K; Calabro SR; Dwyer BJ; Tirnitz-Parker JE; Watkins DN; Warner FJ; Shackel NA; McCaughan GW
J Hepatol; 2014 Jan; 60(1):143-51. PubMed ID: 23978713
[TBL] [Abstract][Full Text] [Related]
8. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
9. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
10. Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein.
Sinha N; Chowdhury S; Sarkar RR
J Biomol Struct Dyn; 2018 Aug; 36(11):2917-2937. PubMed ID: 28849750
[TBL] [Abstract][Full Text] [Related]
11. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.
Arnhold V; Boos J; Lanvers-Kaminsky C
Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311
[TBL] [Abstract][Full Text] [Related]
12. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
13. Hedgehog Inhibitors Suppress Osteoclastogenesis in In Vitro Cultures, and Deletion of
Kohara Y; Haraguchi R; Kitazawa R; Imai Y; Kitazawa S
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326611
[TBL] [Abstract][Full Text] [Related]
14. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
16. A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo.
Zárate AM; Espinosa-Bustos C; Guerrero S; Fierro A; Oyarzún-Ampuero F; Quest AFG; Di Marcotullio L; Loricchio E; Caimano M; Calcaterra A; González-Quiroz M; Aguirre A; Meléndez J; Salas CO
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445078
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol.
Wang F; Stappenbeck F; Matsui W; Parhami F
J Cell Biochem; 2017 Mar; 118(3):499-509. PubMed ID: 27490478
[TBL] [Abstract][Full Text] [Related]
18. The Role of Smoothened in Cancer.
Jeng KS; Sheen IS; Leu CM; Tseng PH; Chang CF
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962123
[TBL] [Abstract][Full Text] [Related]
19. Design of Hedgehog pathway inhibitors for cancer treatment.
Bariwal J; Kumar V; Dong Y; Mahato RI
Med Res Rev; 2019 May; 39(3):1137-1204. PubMed ID: 30484872
[TBL] [Abstract][Full Text] [Related]
20. Targeting GLI factors to inhibit the Hedgehog pathway.
Infante P; Alfonsi R; Botta B; Mori M; Di Marcotullio L
Trends Pharmacol Sci; 2015 Aug; 36(8):547-58. PubMed ID: 26072120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
